Wire · opportunities
Dolutegravir Antiretroviral Receives FDA Approval for Newborns With HIV
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has approved dolutegravir for use in newborns under 4 weeks old with HIV, making it the first second-generation integrase strand transfer inhibitor available for this age group. This approval offers a more robust and preferred antiretroviral therapy option for treating HIV in newborns, based on safety and efficacy demonstrated in the IMPAACT 2023 study.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 26 Aug 2026 and 28 Aug 2026.
◆ ◆ The Wire takeaway
You now have access to a simpler, safer first-line HIV treatment for newborns with FDA approval cleared. This opens immediate new opportunities to serve a critical early-life patient group with a preferred drug officially cleared for their age.
◆ Coverage
3 sources · first reported 26 Aug 2026 · latest 28 Aug 2026
◆ Related on Wire
◆ Topics